Global Influenza Market to Reach $6.5 billion by 2022

April 24, 2018

WELLESLEY, Mass., April 24, 2018– A global aging population and the demand for vaccinations, treatments and diagnoses are helping to drive growth of the worldwide influenza market, according to a report by BCC Research.

The industry is expected to see a compound annual growth rate (CAGR) of 3.0% through 2022, when it could be worth $6.5 billion, according to the report The Global Influenza Market.

Major players in the market include Alere Inc., AstraZeneca Co., Becton Dickinson Co., Cepheid Inc., GlaxoSmithKline Plc., Luminex Corp., Mylan, Orasure Technologies, Quidel Corp., Hoffmann-La Roche, Sanofi and Seqirus.

Research Highlights

  • Therapeutics will lead the market in growth, with a CAGR through 2022 of 4.0%, while vaccines lead the market in size, with a 2022 value of $4.5 billion.
  • Significant trends influencing the global influenza market include the H1N1 outbreak, avian flu surveillance, antiviral resistance, recreated viruses, epidemic and pandemic preparedness, and cell-based and recombinant products.
  • In the U.S. alone, annual influenza rates total about 5% to 20% of the population, hospitalizes around 200,000 people and causes an average of 36,000 deaths.

“Worldwide seasonal flu epidemics can total up to 15% of the population (upper-respiratory infection), of which around 3 million to 5 million cases are classified as severe,” said report author and BCC Research analyst Melissa Elder. “In December 2017, the World Health Organization (WHO) updated its earlier estimates to as many as 650,000 influenza-related deaths annually, with a range of 290,000 to 650,000 deaths from respiratory complications. This is up from the previous estimate of 500,000 deaths and a range of between 250,000 and 500,000 cases.”

Market Driven in Part by Worldwide Pandemics

Uneven growth in the market is partly due to the presence of epidemics and pandemics. Of particular note was the H1N1 outbreak in 2009, which reached a World Health Organization pandemic level 6 response and caused more than 125 deaths in the United States. The virus was able to spread because no vaccine was available to treat it; it was not until later in the season that a vaccine was available.

Editors/reporters requesting analyst interviews should contact

The Global Influenza Market( PHM049E )
Publish Date: Apr 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.